E78 I25
Conditions
Interventions
Group 1: As part of a nationwide survey in cardiology practices, all patients with documented CHD and a confirmed diagnosis of hyperlipoproteinemia will have their cholesterol levels and the correspon
Sponsors
BNK Service GmbH
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Signed declaration of consent from the patient Confirmed diagnosis of CHD Confirmed diagnosis of hyperlipoproteinemia > 12 months and At least one lipid-lowering therapy in the last 12 months prescribed
Exclusion criteria
Exclusion criteria: Existing pregnancy Lipidapheresis therapy (current or in the past) Participation in any interventional study with active lipid-lowering therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. presentation of the achievement of ESC guideline-compliant LDL target values and medication regimens (incl. dosage) in the so-called “real world scenario” 2. documentation of the actual lipid parameters and drug prescriptions | — |
Secondary
| Measure | Time frame |
|---|---|
| Were measures implemented to increase adherence and awareness of the importance of lipid-lowering therapy in the participating practices in order to increase the proportion of patients in the target value range and on combination therapies? | — |
Countries
Germany
Contacts
Public ContactMatthias Paul
UKM Marienhospital Steinfurt
Outcome results
None listed